Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2022 Dec 30;132(2):208–222. doi: 10.1161/CIRCRESAHA.122.321153

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2023 The Authors.

Circulation Research is published on behalf of the American Heart Association, Inc., by Wolters Kluwer Health, Inc. This is an open access article under the terms of the Creative Commons Attribution Non-Commercial-NoDerivs License, which permits use, distribution, and reproduction in any medium, provided that the original work is properly cited, the use is noncommercial, and no modifications or adaptations are made.

PMC Copyright notice

Figure 3. — Cardiomyocyte-specific overexpression of ASPP1 aggravates cardiac I/R injury. A, The mRNA (Student t test) and protein (Mann-Whitney U test) levels of ASPP1 in cardiac tissues of mice subjected to 45 minutes ischemia followed by 24 hours reperfusion (I/R); n=6. B, The mRNA and protein levels of ASPP1 in neonatal mouse ventricular cardiomyocytes (NMVCs) subjected to H/R (Student t test); n=9 for mRNA level; n=6 for protein level. C, The protein levels of E2F1 in I/R hearts and NMVCs treated with H/R stimulation by Western blot (Student t test); n=6. D, Transfection of E2F1 siRNA inhibited the mRNA (Kruskal-Wallis, followed by false discovery rate [FDR] method of Benjamini and Hochberg test) and protein (1-way ANOVA, followed by Tukey post hoc multicomparisons test) expression of ASPP1 in NMCMs exposed to H/R by quantitative real-time PCR (qRT-PCR) and Western blot assay; n=5 for mRNA level; n=6 for protein level. E, The protein levels of ASPP1 in wild type (WT) and ASPP1 transgenic mice by Western blot (Mann-Whitney U test); n=6. F, Cardiac function of wild type (WT) and ASPP1 transgene mice after I/R injury by echocardiography (2-way ANOVA, followed by Tukey post hoc multicomparisons test); n=9. G, Infarct area of I/R mice by 2,3,5-triphenyltetrazolium chloride (TTC) staining (Student t test); n=10. Scale bar=2 mm. H, Serum LDH and creatine kinase isoenzyme MB (CKMB) levels (2-way ANOVA, followed by Tukey post hoc multicomparisons test); n=10 (WT+Sham and ASPP1 transgene+Sham); n=12 (WT+IR and ASPP1 transgene+I/R) for LDH assay; n=9 for CKMB assay. I, Caspase-3 activity detected by ELISA assay (2-way ANOVA, followed by Tukey post hoc multicomparisons test); n=9. J, The protein levels of Bcl2 and Bax detected by Western blot (2-way ANOVA, followed by Tukey post hoc multicomparisons test); n=6. K, Immunofluorescent staining was performed to analyze the effect of ASPP1 transgene on p53 nuclear translocation in isolated adult cardiomyocytes after cardiac I/R injury (2-way ANOVA, followed by Tukey post hoc multicomparisons test); n=6. ns, not significant. Scale bar=20 μm. ASPP1 indicates apoptosis stimulating of p53 protein 1; DAPI, 4′,6-diamidino-2-phenylindole; EF, ejection fraction; FS, fractional shortening; H/R, hypoxia/reoxygenation; and I/R, ischemia/reperfusion.